{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+2+of+Aluminum+Adjuvant&page=2", "query": { "intervention": "Dose 2 of Aluminum Adjuvant", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 40, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+2+of+Aluminum+Adjuvant&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+2+of+Aluminum+Adjuvant&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T16:25:22.044Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05901636", "title": "A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza Prevention" ], "interventions": [ { "name": "INFLUENZA G1 mHA", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Al(OH)3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 170, "start_date": "2023-05-17", "completion_date": "2024-08-19", "has_results": true, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-10-04T16:25:22.044Z", "location_count": 4, "location_summary": "Miami Lakes, Florida • Lenexa, Kansas • Metairie, Louisiana + 1 more", "locations": [ { "city": "Miami Lakes", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05901636" }, { "nct_id": "NCT02304185", "title": "Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "gp140, 50 mcg", "type": "BIOLOGICAL" }, { "name": "gp140, 50 mcg + Adjuvant", "type": "BIOLOGICAL" }, { "name": "gp140, 250 mcg", "type": "BIOLOGICAL" }, { "name": "gp140, 250 mcg + Adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Crucell Holland BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 50, "start_date": "2014-12", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-06-06", "last_synced_at": "2026-10-04T16:25:22.044Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02304185" }, { "nct_id": "NCT01666652", "title": "A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dengue Fever" ], "interventions": [ { "name": "4 µg TDENV-PIV with Alum adjuvant", "type": "BIOLOGICAL" }, { "name": "1 µg TDENV-PIV with AS03B1 adjuvant", "type": "BIOLOGICAL" }, { "name": "Phosphate buffered saline", "type": "OTHER" }, { "name": "1 µg TDENV-PIV with Alum adjuvant", "type": "BIOLOGICAL" }, { "name": "1 µg TDENV-PIV with AS01E1 adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "U.S. Army Medical Research and Development Command", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 100, "start_date": "2012-09", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2019-01-25", "last_synced_at": "2026-10-04T16:25:22.044Z", "location_count": 1, "location_summary": "Silver Spring, Maryland", "locations": [ { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01666652" }, { "nct_id": "NCT01995617", "title": "Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Streptococcus Pneumoniae" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "GEN-004 Low Dose", "type": "BIOLOGICAL" }, { "name": "GEN-004 Low Dose + Adjuvant", "type": "BIOLOGICAL" }, { "name": "GEN-004 Mid Dose", "type": "BIOLOGICAL" }, { "name": "GEN-004 Mid Dose + Adjuvant", "type": "BIOLOGICAL" }, { "name": "GEN-004 High Dose", "type": "BIOLOGICAL" }, { "name": "GEN-004 High Dose + Adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genocea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 90, "start_date": "2013-11", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-12-11", "last_synced_at": "2026-10-04T16:25:22.044Z", "location_count": 1, "location_summary": "Saint Paul, Minnesota", "locations": [ { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01995617" }, { "nct_id": "NCT04915768", "title": "Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CH505 TF chTrimer", "type": "BIOLOGICAL" }, { "name": "3M-05-AF", "type": "BIOLOGICAL" }, { "name": "Aluminum hydroxide suspension", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 51, "start_date": "2023-01-23", "completion_date": "2025-07-15", "has_results": true, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-10-04T16:25:22.044Z", "location_count": 3, "location_summary": "Decatur, Georgia • Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04915768" }, { "nct_id": "NCT03547167", "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "V114", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "PNEUMOVAX™23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 1515, "start_date": "2018-07-16", "completion_date": "2020-01-20", "has_results": true, "last_update_posted_date": "2021-01-15", "last_synced_at": "2026-10-04T16:25:22.044Z", "location_count": 38, "location_summary": "Chinle, Arizona • Fort Defiance, Arizona • Glendale, Arizona + 34 more", "locations": [ { "city": "Chinle", "state": "Arizona" }, { "city": "Fort Defiance", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Whiteriver", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03547167" }, { "nct_id": "NCT03565900", "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "V114", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "PNEUMOVAX™23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 277, "start_date": "2018-09-12", "completion_date": "2021-11-04", "has_results": true, "last_update_posted_date": "2023-07-28", "last_synced_at": "2026-10-04T16:25:22.044Z", "location_count": 13, "location_summary": "Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 10 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03565900" }, { "nct_id": "NCT03382418", "title": "Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "gp145 C.6980 Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Aluminum Hydroxide Adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 45, "start_date": "2017-12-27", "completion_date": "2019-09-25", "has_results": true, "last_update_posted_date": "2021-10-08", "last_synced_at": "2026-10-04T16:25:22.044Z", "location_count": 3, "location_summary": "New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03382418" }, { "nct_id": "NCT02315703", "title": "Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Mos.HIV", "type": "BIOLOGICAL" }, { "name": "MVA-Mosaic", "type": "BIOLOGICAL" }, { "name": "gp140 DP Low-dose", "type": "BIOLOGICAL" }, { "name": "gp140 DP High-dose", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 393, "start_date": "2014-12-22", "completion_date": "2022-03-28", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-04T16:25:22.044Z", "location_count": 5, "location_summary": "Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02315703" }, { "nct_id": "NCT06796686", "title": "Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "426c.Mod.Core-C4b", "type": "BIOLOGICAL" }, { "name": "HxB2.WT.Core-C4b", "type": "BIOLOGICAL" }, { "name": "3M-052-AF adjuvant", "type": "BIOLOGICAL" }, { "name": "Aluminum hydroxide suspension (Alum) adjuvant", "type": "OTHER" }, { "name": "Diluent", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 42, "start_date": "2025-03-17", "completion_date": "2027-01-15", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-10-04T16:25:22.044Z", "location_count": 6, "location_summary": "San Francisco, California • Atlanta, Georgia • Decatur, Georgia + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06796686" } ] }